Predicting treatment response in chronic, acquired demyelinating neuropathies

References

• Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve24, 311–324 (2001).
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Bouche P, Cornblath DR et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur. J. Neurol.13, 326–332 (2006).
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch. Neurol.46, 878–884 (1989).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology48, 321–328 (1997).
   PubMed Web of Science ®Google Scholar
• McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain110(Pt 6), 1617–1630 (1987).
   PubMed Web of Science ®Google Scholar
• Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology54, 615–620 (2000).
   PubMed Web of Science ®Google Scholar
• Saperstein DS, Amato AA, Wolfe GI et al. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis–Sumner syndrome. Muscle Nerve22, 560–566 (1999).
   PubMed Web of Science ®Google Scholar
• Viala K, Renie L, Maisonobe T et al. Follow-up study and response to treatment in 23 patients with Lewis–Sumner syndrome. Brain127, 2010–2017 (2004).
   PubMed Web of Science ®Google Scholar
• Sinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology63, 1662–1669 (2004).
   PubMed Web of Science ®Google Scholar
• Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J. Neurol.250, 714–724 (2003).
   PubMed Web of Science ®Google Scholar
• Donaghy M, Mills KR, Boniface SJ et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J. Neurol. Neurosurg. Psychiatry57, 778–783 (1994).
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RAC, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.CD003906 (2004).
   Google Scholar
• Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.CD001797 (2002).
   Google Scholar
• Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.CD002062 (2002).
   Google Scholar
• Hughes RAC. Management of chronic inflammatory demyelinating polyradiculoneuropathy. Drugs63, 275–287 (2003).
   PubMed Web of Science ®Google Scholar
• McCrone P, Chisholm D, Knapp M et al. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol.10, 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev.CD003280 (2004).
   Google Scholar
• Dyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology35, 1173–1176 (1985).
   PubMed Web of Science ®Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology50, 1778–1783 (1998).
   PubMed Web of Science ®Google Scholar
• Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RAC. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J. Neurol. Neurosurg. Psychiatry77, 544–547 (2006).
   PubMed Web of Science ®Google Scholar
• Hughes RAC, Bouche P, Cornblath DR et al. Response to comment on European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst.11, 90–91 (2006).
   Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Clark BD, Dew RB 3rd, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α2a. Neurology50, 84–87 (1998).
   PubMed Web of Science ®Google Scholar
• Vallat JM, Hahn AF, Leger JM et al. Interferon beta-1a as an investigational treatment for CIDP. Neurology60, S23–S28 (2003).
   PubMedGoogle Scholar
• Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology53, 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Kaplan RL, Albers JW. Treatment of chronic inflammatory demyelinating polyneuropathy. Expert Rev. Neurother.3, 233–246 (2003).
   PubMedGoogle Scholar
• Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain118(Pt 2), 359–368 (1995).
   PubMed Web of Science ®Google Scholar
• Venance SL, Koopman WJ, Hahn AF. Treatment approaches and long-term outcome in a Canadian cohort (1972–2002) with chronic inflammatory demyelinating polyneuropathy (CIDP). J. Peripher. Nerv. Syst.8, S1–S78 (2003).
   Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain119(Pt 4), 1067–1077 (1996).
   PubMed Web of Science ®Google Scholar
• Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol. Sci.21, 31–37 (2000).
   PubMed Web of Science ®Google Scholar
• Koski CL. Initial and long-term management of autoimmune neuropathies. CNS Drugs19, 1033–1048 (2005).
   PubMed Web of Science ®Google Scholar
• Iijima M, Yamamoto M, Hirayama M et al. Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology64, 1471–1475 (2005).
   PubMed Web of Science ®Google Scholar
• Bouchard C, Lacroix C, Plante V et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology52, 498–503 (1999).
   PubMed Web of Science ®Google Scholar
• Odaka M. Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal. Expert Rev. Neurother.6, 365–379 (2006).
   PubMedGoogle Scholar
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J. Peripher. Nerv. Syst.11, 9–19 (2006).
   PubMed Web of Science ®Google Scholar
• Haq RU, Pendlebury WW, Fries TJ, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients. Muscle Nerve27, 465–470 (2003).
   PubMed Web of Science ®Google Scholar
• Sharma KR, Cross J, Farronay O, Ayyar DR, Shebert RT, Bradley WG. Demyelinating neuropathy in diabetes mellitus. Arch. Neurol.59, 758–765 (2002).
   PubMed Web of Science ®Google Scholar
• Sharma KR, Cross J, Ayyar DR, Martinez-Arizala A, Bradley WG. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch. Neurol.59, 751–757 (2002).
   PubMedGoogle Scholar
• Gorson KC, Ropper AH, Adelman LS, Weinberg DH. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy. Muscle Nerve23, 37–43 (2000).
   PubMed Web of Science ®Google Scholar
• Cocito D, Ciaramitaro P, Isoardo G et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J. Neurol.249, 719–722 (2002).
   PubMed Web of Science ®Google Scholar
• Leger JM, Behin A. Multifocal motor neuropathy. Curr. Opin. Neurol.18, 567–573 (2005).
   PubMed Web of Science ®Google Scholar
• European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J. Peripher. Nerv. Syst.11, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Umapathi T, Hughes RAC, Nobile-Orazio E, Leger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst. Rev.CD003217 (2005).
   Google Scholar
• Van Schaik IN, Van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst. Rev.CD004429 (2005).
   Google Scholar
• Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology51, S22–S24 (1998).
   PubMedGoogle Scholar
• Rojas-Garcia R, Gallardo E, de Andres I et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology61, 1814–1816 (2003).
   PubMed Web of Science ®Google Scholar
• Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology63, 2178–2179 (2004).
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatry74, 485–489 (2003).
   PubMed Web of Science ®Google Scholar
• Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J. Neurol. Neurosurg. Psychiatry63, 765–769 (1997).
   PubMed Web of Science ®Google Scholar
• Benedetti L, Grandis M, Nobbio L et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve29, 748–749 (2004).
   PubMed Web of Science ®Google Scholar
• Van den Berg-Vos RM, Franssen H, Wokke JH, Van den Berg LH. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain125, 1875–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E. How long is IVIg effective in multifocal motor neuropathy? Neurology62, 666–668 (2004).
   PubMed Web of Science ®Google Scholar
• Vucic S, Black KR, Chong PS, Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology63, 1264–1269 (2004).
   PubMed Web of Science ®Google Scholar
• Van den Berg-Vos RM, Franssen H, Wokke JH, Van Es HW, Van den Berg LH. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann. Neurol.48, 919–926 (2000).
   PubMed Web of Science ®Google Scholar
• Bouche P, Moulonguet A, Youne-Chennoufi AB et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J. Neurol. Neurosurg. Psychiatry59, 38–44 (1995).
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Corse AM, Cornblath DR et al. Multifocal motor neuropathy: response to human immune globulin. Ann. Neurol.33, 237–242 (1993).
   PubMed Web of Science ®Google Scholar
• Van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry59, 248–252 (1995).
   PubMed Web of Science ®Google Scholar
• Katz JS, Wolfe GI, Bryan WW, Jackson CE, Amato AA, Barohn RJ. Electrophysiologic findings in multifocal motor neuropathy. Neurology48, 700–707 (1997).
   PubMed Web of Science ®Google Scholar
• Azulay JP, Rihet P, Pouget J et al. Long term follow up of multifocal motor neuropathy with conduction block under treatment. J. Neurol. Neurosurg. Psychiatry62, 391–394 (1997).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Cappellari A, Meucci N et al. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J. Neurol. Neurosurg. Psychiatry72, 761–766 (2002).
   PubMed Web of Science ®Google Scholar
• Katz JS, Barohn RJ, Kojan S et al. Axonal multifocal motor neuropathy without conduction block or other features of demyelination. Neurology58, 615–620 (2002).
   PubMed Web of Science ®Google Scholar
• Fischer D, Grothe C, Schmidt S, Schroder R. On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy. J. Neurol.251, 1204–1207 (2004).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Manfredini E, Carpo M et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann. Neurol.36, 416–424 (1994).
   PubMed Web of Science ®Google Scholar
• Vital C, Vital A, Bouillot S et al. Uncompacted myelin lamellae in peripheral nerve biopsy. Ultrastruct. Pathol.27, 1–5 (2003).
   PubMed Web of Science ®Google Scholar
• Lunn M, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst. Rev.CD002827 (2006).
   Google Scholar
• Comi G, Roveri L, Swan A et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J. Neurol.249, 1370–1377 (2002).
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Quarles RH, Farrer RG et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann. Neurol.40, 792–795 (1996).
   PubMed Web of Science ®Google Scholar
• Mariette X, Chastang C, Clavelou P, Louboutin JP, Leger JM, Brouet JC. A randomised clinical trial comparing interferon-a and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J. Neurol. Neurosurg. Psychiatry63, 28–34 (1997).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Low PA, Windebank AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N. Engl. J. Med.325, 1482–1486 (1991).
   Google Scholar
• Oksenhendler E, Chevret S, Leger JM, Louboutin JP, Bussel A, Brouet JC. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J. Neurol. Neurosurg. Psychiatry59, 243–247 (1995).
   PubMed Web of Science ®Google Scholar
• Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology45, 1577–1580 (1995).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain123(Pt 4), 710–717 (2000).
   PubMed Web of Science ®Google Scholar
• Notermans NC, Lokhorst HM, Franssen H et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology47, 1227–1233 (1996).
   PubMed Web of Science ®Google Scholar
• Kararizou E, Karandreas N, Davaki P, Davou R, Vassilopoulos D. Polyneuropathies in teenagers: a clinicopathological study of 45 cases. Neuromuscul. Disord.16, 304–307 (2006).
   PubMed Web of Science ®Google Scholar
• Mariette X, Brouet JC, Chevret S et al. A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J. Neurol. Neurosurg. Psychiatry69, 279–280 (2000).
   PubMed Web of Science ®Google Scholar
• Renaud S, Gregor M, Fuhr P et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve27, 611–615 (2003).
   PubMed Web of Science ®Google Scholar
• Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk. Lymphoma47, 859–864 (2006).
   PubMed Web of Science ®Google Scholar
• Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve32, 378–379 (2005).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Francomano E, Daverio R et al. Anti-myelin-associated glycoprotein IgM antibody titers in neuropathy associated with macroglobulinemia. Ann. Neurol.26, 543–550 (1989).
   PubMed Web of Science ®Google Scholar
• Van den Berg L, Hays AP, Nobile-Orazio E et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve19, 637–643 (1996).
   PubMed Web of Science ®Google Scholar
• Wilson HC, Lunn MP, Schey S, Hughes RAC. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J. Neurol. Neurosurg. Psychiatry66, 575–580 (1999).
   PubMed Web of Science ®Google Scholar
• Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology52, 1701–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve24, 778–786 (2001).
   PubMed Web of Science ®Google Scholar
• Chan YC, Allen DC, Fialho D, Mills KR, Hughes RAC. Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry77, 114–116 (2006).
   PubMed Web of Science ®Google Scholar